Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Sputnik Light is the first component of Sputnik V
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Manipal Hospitals partners with ConnectedLife, leveraging Fitbit wearable technology, for Continuity of Care Post-High-Risk Surgeries built with Google Cloud
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
The announcement follows recent authorization of the Company's mRNA COVID-19 vaccine in Australia and the European Union for children aged 6-11 years
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
OCE+ uses IQVIA’s industry-leading data and advanced analytics to deliver AI-driven recommendations directly into the daily workflows of life sciences commercial teams
Subscribe To Our Newsletter & Stay Updated
